NEW YORK, April 27, 2026

Fathom Therapeutics has announced the successful completion of an oversubscribed $47 million Series A financing round, marking a major milestone in advancing AI- and physics-enabled drug discovery technologies. The funding, led by Sutter Hill Ventures with participation from leading investors, will support the company’s mission to translate cutting-edge computational science into next-generation small molecule medicines, accelerating innovation in pharmaceutical research and development.

Series A Funding Fuels Next-Generation Drug Discovery

The $47 million Series A financing highlights strong investor confidence in Fathom’s unique approach to drug design, which combines quantum chemistry, artificial intelligence, and high-resolution protein modeling to create novel therapeutics. The company’s proprietary platform, Microcosmos, enables simulation of protein dynamics at atomic resolution, overcoming the limitations of traditional drug discovery methods that rely on static protein structures.

By accelerating protein modeling processes by up to 10,000 times without compromising accuracy, the platform allows researchers to generate and optimize drug candidates with unprecedented speed and precision. This capability is particularly valuable in addressing previously “undruggable” targets, opening new opportunities for therapeutic innovation across a range of disease areas.

AI and Physics Converge to Redefine Molecular Design

Advertisement

cGxPJobs Banner

Fathom’s Microcosmos platform represents a paradigm shift in drug discovery, integrating physics-based simulations with machine learning to predict how molecules behave within living cells. This approach enables the generative design of small molecules that can precisely modulate protein function, leading to more effective and targeted therapies.

Early results demonstrate the platform’s potential to rapidly generate high-quality drug candidates, with one program producing potent and selective molecules within just six weeks. These candidates are now being optimized for clinical development, showcasing the platform’s ability to translate computational insights into real-world therapeutic solutions.

The company’s leadership team brings extensive experience in advancing drugs to the clinic, including multiple FDA-approved therapies, further strengthening its ability to move discoveries from concept to commercialization. The establishment of a Scientific Advisory Board comprising leading experts in biotechnology and computational science underscores its commitment to scientific excellence and innovation.

Scaling Innovation to Address Unmet Medical Needs

The newly secured funding will enable Fathom to expand its internal drug discovery programs and scale its “lab-in-the-loop” capabilities, integrating computational design with experimental validation to accelerate the development pipeline. The company is focusing on high-impact diseases with significant unmet medical needs, aiming to deliver therapies that were previously considered impossible to develop.

This advancement reflects a broader industry trend toward the integration of AI and advanced computational tools in pharmaceutical research, driving efficiency, reducing costs, and improving success rates in drug development. By leveraging these technologies, Fathom aims to shorten development timelines and enhance the precision of therapeutic design, ultimately benefiting patients and healthcare systems.

From a cGxP perspective, the evolution of AI-driven drug discovery underscores the importance of robust validation, data integrity, and regulatory compliance in emerging technologies, ensuring that innovative approaches meet the rigorous standards required for clinical development and approval.

Fathom Therapeutics’ progress positions it as a key innovator in the bio-pharma landscape, with the potential to redefine how medicines are discovered and developed in the era of digital and computational biology.

Source: Fathom Therapeutics press release